Dostarlimab for the treatment of endometrium cancer and other solid tumors
Copyright 2021 Clarivate Analytics..
The use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lung cancer or melanoma. The preliminary results, particularly in endometrial cancer, show a high affinity against PD-1 with encouraging clinical activity. Here we summarize the development of this compound as well as the current preclinical and clinical data and potential future development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:57 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 57(2021), 3 vom: 01. März, Seite 187-197 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rubio-Pérez, J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.03.2021 Date Revised 19.03.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2021.57.3.3233363 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322858399 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322858399 | ||
| 003 | DE-627 | ||
| 005 | 20231225182931.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2021.57.3.3233363 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1076.xml |
| 035 | |a (DE-627)NLM322858399 | ||
| 035 | |a (NLM)33729216 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rubio-Pérez, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dostarlimab for the treatment of endometrium cancer and other solid tumors |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.03.2021 | ||
| 500 | |a Date Revised 19.03.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2021 Clarivate Analytics. | ||
| 520 | |a The use of monoclonal antibodies directed against programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), widely extends to a large number of tumors such as melanoma, non-small cell lung, renal or lymphomas, among others. Some of them are already approved as first- or second-line treatment, as pembrolizumab, nivolumab or cemiplimab. Dostarlimab is an investigational humanized anti-PD-1 that is being developed both in monotherapy and as combination therapy, for gynecological tumors but also for lung cancer or melanoma. The preliminary results, particularly in endometrial cancer, show a high affinity against PD-1 with encouraging clinical activity. Here we summarize the development of this compound as well as the current preclinical and clinical data and potential future development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-programmed cell death protein 1 (PD-1) therapy | |
| 650 | 4 | |a Cancer immunotherapy | |
| 650 | 4 | |a Dostarlimab | |
| 650 | 4 | |a Endometrial cancer | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a Monoclonal antibodies | |
| 650 | 4 | |a Solid tumors therapy | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 700 | 1 | |a Hernández, R |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández, T |e verfasserin |4 aut | |
| 700 | 1 | |a Doger, B |e verfasserin |4 aut | |
| 700 | 1 | |a Casado, V |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 57(2021), 3 vom: 01. März, Seite 187-197 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:57 |g year:2021 |g number:3 |g day:01 |g month:03 |g pages:187-197 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2021.57.3.3233363 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 57 |j 2021 |e 3 |b 01 |c 03 |h 187-197 | ||